Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)
Rosalba Torrisi(IRCCS Humanitas Research Hospital), Armando Santoro(IRCCS Humanitas Research Hospital), Maria Rosaria Valerio(Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo), Rossana Gueli, Giulia Bianchi, Rita De Sanctis(Humanitas University), Laura Pizzuti, Raffaella Palumbo(Fondazione Salvatore Maugeri), Alessandra Fabi(Agostino Gemelli University Polyclinic), Laura Cortesi(Azienda Ospedaliero-Universitaria di Modena), Barbara Tagliaferri(Istituti Clinici Scientifici Maugeri), V. Leonardi(University of Palermo), Marina Elena Cazzaniga(Azienda Ospedaliera San Gerardo), Patrizia Vici(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 4
Related Papers
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743